Aura Biosciences (AURA) Expected to Release Earnings on Wednesday

Aura Biosciences (NASDAQ:AURA) is projected to post its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect Aura Biosciences to post earnings of ($0.41) per share for the quarter. Individuals can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, August 10, 2026 at 4:00 PM ET.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.10). On average, analysts expect Aura Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Aura Biosciences Trading Up 1.6%

NASDAQ:AURA opened at $7.15 on Wednesday. The firm has a market capitalization of $739.24 million, a price-to-earnings ratio of -4.11 and a beta of 0.40. Aura Biosciences has a 1-year low of $4.73 and a 1-year high of $9.53. The business’s fifty day moving average price is $6.92 and its 200 day moving average price is $6.62.

Analyst Ratings Changes

Several equities analysts have weighed in on AURA shares. Weiss Ratings raised Aura Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 14th. HC Wainwright increased their price target on shares of Aura Biosciences from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Wall Street Zen cut shares of Aura Biosciences from a “hold” rating to a “sell” rating in a report on Sunday, July 12th. Finally, Leerink Partners set a $17.00 price objective on shares of Aura Biosciences in a research report on Tuesday, May 12th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Aura Biosciences presently has an average rating of “Hold” and an average price target of $20.50.

Insiders Place Their Bets

In other Aura Biosciences news, insider Anthony S. Gibney sold 12,824 shares of the business’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $6.42, for a total value of $82,330.08. Following the transaction, the insider owned 265,354 shares in the company, valued at $1,703,572.68. The trade was a 4.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Matrix Capital Management Comp sold 6,922,870 shares of the firm’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $5.64, for a total value of $39,044,986.80. The SEC filing for this sale provides additional information. 1.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Aura Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC lifted its stake in Aura Biosciences by 49.3% in the second quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock valued at $40,000 after acquiring an additional 2,104 shares during the last quarter. Water Island Capital LLC acquired a new position in shares of Aura Biosciences during the 3rd quarter worth $64,000. Invesco Ltd. bought a new position in shares of Aura Biosciences during the 2nd quarter valued at $76,000. BNP Paribas Financial Markets raised its holdings in shares of Aura Biosciences by 286.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 13,499 shares of the company’s stock valued at $85,000 after purchasing an additional 10,007 shares in the last quarter. Finally, Bridgeway Capital Management LLC bought a new position in shares of Aura Biosciences during the 2nd quarter valued at $102,000. Institutional investors own 96.75% of the company’s stock.

About Aura Biosciences

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.